Actinium Pharmaceuticals Inc is categorized under in New York City, NY and active since 2000.
Actinium Pharmaceuticals Inc was established in 2000, and today employs 1 to 4, earning Unknown per year. This is a business, which does work in the B2C market, and is classified as a , under code number 3254120 by the NAICS.
If you are seeking more information, feel free to contact Sergio Traversa, Chief Executive Officer at the company’s headquarters by writing to 501 5th Avenue # 3, New York City, New York NY 10017 or by phoning (646) 459-4201. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Actinium Pharmaceuticals Inc |
| Contact Person: | Sergio Traversa, Chief Executive Officer |
| Address: | 501 5th Avenue # 3, New York City, New York 10017 |
| Phone Number: | (646) 459-4201 |
| Website Address: | actiniumpharmaceuticals.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 2000 |
| Location Type: | Headquarters |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | |
| SIC Code: | 8069 |
| NAICS Code: | 3254120 |
| Share This Business: |
Actinium Pharmaceuticals Inc was started in 2000 to provide professional under the SIC code 8069 and NAICS code 3254120. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Sergio Traversa, Chief Executive Officer for inquiries that concern Actinium Pharmaceuticals Inc by calling the company number (646) 459-4201, as your correspondence is most welcome. Additionally, the physical location of the headquarters of Actinium Pharmaceuticals Inc can be found at the coordinates 40.753438,-73.980838 as well as the street address 501 5th Avenue # 3 in New York City, New York 10017.
For its online presence, you may visit Actinium Pharmaceuticals Inc’s website at actiniumpharmaceuticals.com and engage with its social media outlets through on Twitter and on Facebook.